FDA supplemental approval: Buprenorphine AND Naloxone (REMS)

AI Summary

This is an FDA supplemental approval (ANDA) granted on 14 August 2026 for buprenorphine–naloxone sublingual tablets in two strengths (2/0.5 mg and 8/2 mg base) manufactured by Hikma, submitted under a REMS (Risk Evaluation and Mitigation Strategy) classification. The record documents the regulatory action and approved product specifications but does not contain or report clinical trial efficacy, safety, or comparative outcome data.

Plain-language summary

FDA supplemental approval of a buprenorphine–naloxone combination tablet under a Risk Evaluation and Mitigation Strategy (REMS); this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval allows an additional manufacturer (Hikma) to market generic buprenorphine–naloxone sublingual tablets under an ANDA pathway. Clinicians should note that this is a regulatory approval action; it does not provide new clinical efficacy or safety data and does not change the clinical use of buprenorphine–naloxone combination therapy.

Caveats

• Record does not contain or report clinical trial data, efficacy outcomes, safety results, or comparative effectiveness
• REMS submission class indicates risk management requirements but specific REMS details are not provided in this record
• No sample size, patient population, or follow-up duration reported
• This is an approval action, not a study; no strength of evidence can be inferred for the underlying indication or dosing

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.